Genetic Engineering, Immune Response, Protein and Trials

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein

Protein Vaccination Vaccine Immune Response

mRNA Cancer Vaccines and Therapies: An Overview

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. One strategy proposed the use of synthetic mRNA or modified mRNA analogs, which can enhance the stability and protein expression of mRNA.

Vaccination

Vaccination Vaccine Protein Antibody

Researchers successfully exploit virus against advanced cancers

Drug Discovery World

SEPTEMBER 9, 2022

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. The genetically engineered RP2 virus, which is injected directly into the tumours, is designed to have a dual action against tumours.

Research

Research Genetic Engineering Engineer Immune Response

AstraZeneca-Oxford COVID-19 Vaccine Shows High Efficacy

XTalks

NOVEMBER 23, 2020

Severe cases of the infection did not occur among trial participants, nor were any hospitalizations reported. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Q&A with Mark Garner: The golden age of cancer research

Drug Discovery World

JULY 5, 2023

Decades of research on the cellular and molecular mechanisms of how the immune system detects and kills cancerous or pre-cancerous cells, known as immune surveillance, and the factors which modulate that response, have led to understanding how we can enable a patient’s own immune system to fight cancer more efficiently in different ways.

Research

Research Protein Scientist Immune Response

The New Frontier in Drug Development: Understanding Biologics and Small Molecules

Cloudbyz

MARCH 5, 2024

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.

Development

Development Drugs Manufacturing Immune Response

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. Novavax expects to begin its pivotal Phase 3 clinical trial in the United States and Mexico by the end of November. and globally.”. About NVX-CoV2373.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. pivotal Phase 3 trial update. South Africa Phase 2b trial update. Mexico pivotal Phase 3 trial update. United Kingdom (U.K.)

Clinical Development

Clinical Development Vaccination Vaccine Development

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. protein-based biologics) and vaccine treatments.

Protein

Protein Engineer Immune Response In-Vivo

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. Novavax, Inc. Government.” About PREVENT-19.

Vaccination

Vaccination Vaccine Trials Immune Response

Experimental vaccine protects against deadly Sudan virus

Drug Discovery World

FEBRUARY 3, 2023

No treatment or vaccine for SUDV disease is licensed, although candidates are in clinical and preclinical trials. In the current studies, the investigators replaced the key EBOV protein in Ervebo with the comparable protein from SUDV. Next, the researchers tested the safety and efficacy of VSV-SUDV in macaques.

Vaccination

Vaccination Vaccine Genetic Engineering Protein

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

JULY 22, 2022

Immunotherapies have become more popular due to their ability to trigger and train the patient’s immune system to recognise and attack tumour cells, provide strong immune responses, and reduce the severity of adverse side effects generally associated with chemotherapies.

In-Vivo

In-Vivo Engineer In-Vitro Antibody

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations.

Vaccination

Vaccination Vaccine Containment Clinical Trials

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations.

Vaccination

Vaccination Vaccine Containment Clinical Trials

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

NOVEMBER 2, 2021

In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours. The BiTE platform is an innovative technology designed to engage the immune system against numerous stages and types of cancers. Five bsAbs delivering payloads entered clinical trials in 2019, four of which targeted solid tumours.

Antibody

Antibody Immune Response Production Engineer

Clinical Research Informer

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

mRNA Cancer Vaccines and Therapies: An Overview

Trending Sources

Researchers successfully exploit virus against advanced cancers

AstraZeneca-Oxford COVID-19 Vaccine Shows High Efficacy

Q&A with Mark Garner: The golden age of cancer research

The New Frontier in Drug Development: Understanding Biologics and Small Molecules

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

Novavax Announces COVID-19 Vaccine Clinical Development Progress

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

Experimental vaccine protects against deadly Sudan virus

How mice with humanised immune systems are advancing cell-based immunotherapy

Biopharma Leaders Unite To Stand With Science

Biopharma Leaders Unite To Stand With Science

Using bispecific antibodies to advance cancer immunotherapy

Stay Connected